

Jacob M Van Laar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/260335/publications.pdf>

Version: 2024-02-01

166
papers

6,752
citations

109264

35
h-index

69214

77
g-index

168
all docs

168
docs citations

168
times ranked

6941
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on EULAR definition of difficult-to-treat rheumatoid arthritis" by Novella-Navarro et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e56-e56.	0.5	2
2	NT-proBNP and sRAGE levels in early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 243-249.	0.6	2
3	Development and Validation of Rheumatoid Arthritis Disease Activity Indices Including HandScan (Optical Spectral Transmission) Scores. <i>Arthritis Care and Research</i> , 2022, 74, 1493-1499.	1.5	3
4	Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 1948-1956.	0.9	6
5	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.5	104
6	Information preferences about treatment options in diffuse cutaneous systemic sclerosis: A Delphi consensus study. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 239719832110433.	1.0	1
7	Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial. <i>Journal of Controlled Release</i> , 2022, 341, 548-554.	4.8	6
8	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 103-112.	0.4	3
9	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.4	12
10	Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. <i>Rheumatology</i> , 2022, 61, 3552-3566.	0.9	19
11	Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. <i>Rheumatology</i> , 2022, 61, 4232-4244.	0.9	12
12	Microarray analysis of autoantibodies can identify future Systemic Lupus Erythematosus patients. <i>Human Immunology</i> , 2022, 83, 509-514.	1.2	1
13	Classification of rheumatoid arthritis into active or inactive with a modified Disease Activity score, for future use as a treat-to-target tool, with a HandScan score replacing joint counts.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
14	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
15	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
16	Do Patients with Psoriatic Arthritis Have More Severe Skin Disease than Patients with Psoriasis Only? A Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2022, 238, 1108-1119.	0.9	3
17	Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 66-70.	0.4	4
18	Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	2

#	ARTICLE	IF	CITATIONS
19	Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 495-503.	1.0	7
20	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.5	224
21	Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. <i>Rheumatology</i> , 2021, 60, 3778-3788.	0.9	74
22	Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD). <i>Clinical and Experimental Immunology</i> , 2021, 203, 160-173.	1.1	6
23	Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110351.	1.2	8
24	Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. <i>Rheumatology</i> , 2021, 60, 4681-4690.	0.9	20
25	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	3.5	35
26	Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001512.	1.8	42
27	Utility of the HandScan in monitoring disease activity and prediction of clinical response in rheumatoid arthritis patients: an explorative study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab004.	0.3	2
28	Text Mining of Electronic Health Records Can Accurately Identify and Characterize Patients With Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021, 3, 65-71.	0.9	10
29	Current Smoking Negatively Affects the Response to Methotrexate in Rheumatoid Arthritis in a Dose-responsive Way, Independently of Concomitant Prednisone Use. <i>Journal of Rheumatology</i> , 2021, 48, 1504-1507.	1.0	11
30	Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. <i>Rheumatology</i> , 2021, 60, 5105-5116.	0.9	8
31	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. <i>BMJ Open</i> , 2021, 11, e044483.	0.8	11
32	Severe thrombotic microangiopathy after autologous stem cell transplantation in systemic sclerosis: a case report. <i>Rheumatology</i> , 2021, 60, e326-e328.	0.9	2
33	AB0812â€¦BIOMARKERS FOR CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE: A PILOT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1430.1-1431.	0.5	0
34	POS1419â€¦PREDICTIVE FACTORS FOR PULMONARY PROGRESSION IN PATIENTS WITH CONNECTIVE TISSUE DISEASE AND INTERSTITIAL LUNG DISEASE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 993.1-993.	0.5	0
35	AB0914-PAREâ€¦INFORMATION PREFERENCES ABOUT TREATMENT OPTIONS IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A DELPHI CONSENSUS STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1478.3-1479.	0.5	0
36	AB0884-HPRâ€¦PERSONALISED TREATMENT GOALS IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1465.1-1466.	0.5	0

#	ARTICLE	IF	CITATIONS
37	POS0089â€¦..AZD9567 VERSUS PREDNISOLONE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP EFFICACY AND SAFETY STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 253-254.	0.5	0
38	Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon. <i>Arthritis Research and Therapy</i> , 2021, 23, 184.	1.6	14
39	Clinical Practice Audit on the Management of Antineutrophil Cytoplasmic Antibodyâ€œAssociated Vasculitis in the Netherlands. <i>Kidney International Reports</i> , 2021, 6, 2671-2678.	0.4	5
40	Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. <i>Respiratory Medicine</i> , 2021, 187, 106579.	1.3	21
41	Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001511.	1.8	12
42	Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: Three successful cases and review of the literature. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 199-205.	1.0	4
43	Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies. <i>Lupus Science and Medicine</i> , 2021, 8, e000531.	1.1	3
44	Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review. <i>Joint Bone Spine</i> , 2020, 87, 13-23.	0.8	8
45	How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?. <i>Rheumatology</i> , 2020, 59, 1226-1232.	0.9	11
46	2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 39-52.	0.5	506
47	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	2.5	231
48	Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate. <i>Rheumatology</i> , 2020, 59, 2325-2333.	0.9	6
49	Treatment decision-making in diffuse cutaneous systemic sclerosis: a patientâ€™s perspective. <i>Rheumatology</i> , 2020, 59, 2052-2061.	0.9	13
50	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 267-276.	6.3	78
51	From â€œbeing at warâ€œ to â€œgetting back on your feetâ€œ: A qualitative study on experiences of patients with systemic sclerosis treated with hematopoietic stem cell transplantation. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 202-209.	1.0	2
52	B(effector)reaking bad in systemic sclerosis: role of a novel B cell subset. <i>Clinical and Experimental Immunology</i> , 2020, 201, 231-232.	1.1	1
53	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 963-974.	5.2	348
54	Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. <i>RMD Open</i> , 2020, 6, e001344.	1.8	6

#	ARTICLE	IF	CITATIONS
55	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1084-1089.	0.5	32
56	Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 460-463.	0.5	6
57	Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101485.	1.4	11
58	Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 167-178.	3.5	130
59	The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation. <i>Clinical and Experimental Immunology</i> , 2020, 201, 34-39.	1.1	9
60	Health-related quality of life in patients with immune mediated inflammatory diseases: A cross-sectional, multidisciplinary study. <i>Clinical Immunology</i> , 2020, 214, 108392.	1.4	13
61	Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial. <i>Trials</i> , 2020, 21, 313.	0.7	4
62	FR10047â€¦STRATEGIES REGARDING GOAL SETTING AND SELF-MANAGEMENT IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2020 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 599.2-599.	0.5	1
63	SAT0052â€¦THERAPEUTIC STRATEGIES IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2020 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 957-957.	0.5	3
64	Cardiovascular risk in patients with new gout: should we reclassify the risk?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 533-535.	0.4	0
65	Cardiovascular risk in patients with new gout diagnosis: is monosodium urate volume at ankles and feet on dual-energy computed tomography associated with previous cardiovascular events?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 763-766.	0.4	3
66	Preservation of Lung Function Observed in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis. , 2019, , .		3
67	Is There a Place for Hematopoietic Stem Cell Transplantation in Rheumatology?. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 399-416.	0.8	6
68	Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1333-1338.	0.5	15
69	Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review. <i>Current Rheumatology Reports</i> , 2019, 21, 24.	2.1	7
70	Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis. <i>Trials</i> , 2019, 20, 226.	0.7	3
71	Heat Shock Proteins Can Be Surrogate Autoantigens for Induction of Antigen Specific Therapeutic Tolerance in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 10, 279.	2.2	22
72	Second autologous haematopoietic stem cell transplantation in systemic sclerosisâ€”a case report. <i>Rheumatology</i> , 2019, 58, 1305-1307.	0.9	2

#	ARTICLE	IF	CITATIONS
73	Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782.	1.8	91
74	SAT0259â€¦PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND MAJOR ADVERSE EVENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENTRE STUDY. , 2019, , .		0
75	THU0198â€¦EFFECTIVENESS OF REMISSION-INDUCTION STRATEGIES FOR EARLY RHEUMATOID ARTHRITIS (RA): A SYSTEMATIC LITERATURE REVIEW. , 2019, , .		0
76	SAT0296â€¦FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN. , 2019, , .		3
77	FRIO135â€¦INTRAVENOUS PEGYLATED LIPOSOMAL PREDNISOLONE SODIUM PHOSPHATE MORE EFFECTIVE THAN INTRAMUSCULAR INJECTION OF METHYLPREDNISOLONE ACETATE IN TREATING RA PATIENTS WHO ARE EXPERIENCING A FLARE: A PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, ACTIVE CONTROLLED, MULTI-CENTER STUDY. , 2019, , .		0
78	AB0276â€¦IS PREDICTION OF CLINICAL RESPONSE TO METHOTREXATE IN INDIVIDUAL RHEUMATOID ARTHRITIS PATIENTS POSSIBLE? RESULTS OF A SYSTEMATIC LITERATURE REVIEW. , 2019, , .		0
79	OP0050â€¦ADDITIVE VALUE AND DIAGNOSTIC ACCURACY OF DUAL-ENERGY CT FOR THE DIAGNOSIS OF GOUT: A PROSPECTIVE STUDY IN SUBJECTS WITH UNCLASSIFIED MONO OR OLIGOARTHRITIS. , 2019, , .		0
80	Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open, 2019, 5, e001041.	1.8	104
81	Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open, 2019, 5, e001035.	1.8	113
82	Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 142-144.	0.5	6
83	Immunology and systemic sclerosis - Editorial. Immunology Letters, 2018, 195, 1.	1.1	1
84	Optical spectral transmission to assess inflammation in hand and wrist joints of rheumatoid arthritis patients. Rheumatology, 2018, 57, 865-872.	0.9	17
85	Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis. Clinical Rheumatology, 2018, 37, 1879-1884.	1.0	18
86	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.5	50
87	Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. Rheumatology, 2018, 57, 309-317.	0.9	12
88	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	0.9	53
89	Proteomics to predict the response to tumour necrosis factor-Î± inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score. Scandinavian Journal of Rheumatology, 2018, 47, 12-21.	0.6	6
90	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology, 2018, 57, 152-157.	0.9	13

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 212-220.	0.5	236
92	Autologous hematopoietic stem cell transplantation in systemic sclerosis: A reset to tolerance?. <i>Immunology Letters</i> , 2018, 195, 88-96.	1.1	12
93	Targeting of tolerogenic dendritic cells towards heat shock proteins: a novel therapeutic strategy for autoimmune diseases?. <i>Immunology</i> , 2018, 153, 51-59.	2.0	18
94	AB1150...The european reference network on rare and complex connective tissue and musculoskeletal diseases: ern reconnet. , 2018, , .		0
95	THU0119...Smoking is negatively associated with clinical response to concomitant prednisone use in early rheumatoid arthritis. , 2018, , .		0
96	The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies. <i>Arthritis Research and Therapy</i> , 2018, 20, 256.	1.6	10
97	Sjögren's syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000789.	1.8	34
98	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	1.8	38
99	Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology. <i>Arthritis Research and Therapy</i> , 2018, 20, 230.	1.6	25
100	Targeting the TLR4-MD2 axis in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 564-566.	3.5	6
101	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1705-1709.	0.5	83
102	RNA sequencing to predict response to TNF inhibitors reveals possible mechanism for nonresponse in smokers. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 623-633.	1.3	5
103	Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1261-1267.	0.5	32
104	Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1485.	2.2	12
105	Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study. <i>PLoS ONE</i> , 2018, 13, e0201527.	1.1	29
106	Resetting the T Cell Compartment in Autoimmune Diseases With Autologous Hematopoietic Stem Cell Transplantation: An Update. <i>Frontiers in Immunology</i> , 2018, 9, 767.	2.2	13
107	A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol. <i>BMJ Open</i> , 2018, 8, e020479.	0.8	21
108	OUP accepted manuscript. <i>Rheumatology</i> , 2018, 57, 1135-1144.	0.9	60

#	ARTICLE	IF	CITATIONS
109	Predicting Flare Probability in Rheumatoid Arthritis using Machine Learning Methods. , 2018, , .		9
110	FRI0026â€¦U-act-early trial 3 years follow-up. the longer effectiveness of treat-to-target strategies in early ra with tocilizumab, methotrexate, or their combination. , 2018, , .		0
111	SAT0169â€¦No evidence that concomitant glucocorticoid therapy affects efficacy and safety of tocilizumab monotherapy in rheumatoid arthritis clinical trials. , 2018, , .		1
112	Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics. Clinical and Experimental Rheumatology, 2018, 36, 976-983.	0.4	4
113	Haematopoietic stem cell transplantation for autoimmune diseases. Nature Reviews Rheumatology, 2017, 13, 244-256.	3.5	108
114	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.5	107
115	Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. Annals of the Rheumatic Diseases, 2017, 76, 1432-1435.	0.5	28
116	Association of MicroRNAâ€œ18 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 1891-1902.	2.9	67
117	Microbial Dysbiosis in Common Variable Immune Deficiencies: Evidence, Causes, and Consequences. Trends in Immunology, 2017, 38, 206-216.	2.9	47
118	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.5	794
119	Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy. Rheumatology, 2017, 56, 2179-2189.	0.9	5
120	A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo. Journal of Thrombosis and Haemostasis, 2017, 15, 1788-1798.	1.9	19
121	OP0310â€¦Pregnancy outcome in women with systemic lupus erythematosus, a multicenter cohort-study. , 2017, , .		0
122	FRI0664â€¦Influence of joint pathology on optical spectral transmission imaging, assessing inflammation in hand and wrist joints of rheumatoid arthritis patients. , 2017, , .		0
123	Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births. Journal of Immunology Research, 2017, 2017, 1-5.	0.9	33
124	Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study. Journal of Immunology Research, 2017, 2017, 1-9.	0.9	14
125	Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy. Arthritis Research and Therapy, 2017, 19, 170.	1.6	16
126	Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review. PLoS ONE, 2017, 12, e0188810.	1.1	20

#	ARTICLE	IF	CITATIONS
127	Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 221-228.	0.4	5
128	Measurement of antinuclear antibodies and their fine specificities: time for a change in strategy?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 462-470.	0.4	10
129	Knee Joint Distraction Compared to Total Knee Arthroplasty for Treatment of End Stage Osteoarthritis: Simulating Long-Term Outcomes and Cost-Effectiveness. <i>PLoS ONE</i> , 2016, 11, e0155524.	1.1	28
130	Histone Demethylation and Toll-like Receptor 2-Dependent Cross-Talk in Monocytes Promotes Transdifferentiation of Fibroblasts in Systemic Sclerosis Via FcγR2. <i>Arthritis and Rheumatology</i> , 2016, 68, 1493-1504.	2.9	43
131	Evolution of serum cytokine profile after hematopoietic stem cell transplantation in systemic sclerosis patients. <i>Bone Marrow Transplantation</i> , 2016, 51, 1146-1149.	1.3	21
132	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet</i> , The, 2016, 387, 2630-2640.	6.3	505
133	Stem cell transplantation and mesenchymal cells to treat autoimmune diseases. <i>Presse Medicale</i> , 2016, 45, e159-e169.	0.8	23
134	Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. <i>Rheumatology</i> , 2016, 55, 826-839.	0.9	81
135	Cellular Therapies in Systemic Sclerosis: Recent Progress. <i>Current Rheumatology Reports</i> , 2016, 18, 12.	2.1	23
136	Does disease activity add to functional disability in estimation of utility for rheumatoid arthritis patients on biologic treatment?. <i>Rheumatology</i> , 2016, 55, 94-102.	0.9	5
137	Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF- α Inhibitors in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0163087.	1.1	43
138	Building a Tailored, Patient-Guided, Web-Based Self-Management Intervention "ReumaUitgedaagd!"™ for Adults With a Rheumatic Disease: Results of a Usability Study and Design for a Randomized Control Trail. <i>JMIR Research Protocols</i> , 2016, 5, e113.	0.5	10
139	Automated joint space width quantification of hand and wrist joints: a proof of concept study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S34-S39.	0.4	17
140	Computerised versus conventional methodology of radiographic joint destruction assessment in early rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000148.	1.8	2
141	Contribution of the Subjective Components of the Disease Activity Score to the Response to Biologic Treatment in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 923-928.	1.5	12
142	Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 2126-2133.	0.9	35
143	The immunopathology of systemic sclerosis. <i>Seminars in Immunopathology</i> , 2015, 37, 439-441.	2.8	8
144	Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in-vivo study. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 63-69.	0.6	54

#	ARTICLE	IF	CITATIONS
145	Economic evaluation of a tight-control treatment strategy using an imaging device (handscan) for monitoring joint inflammation in early rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 831-8.	0.4	1
146	Concepts of pathogenesis and emerging treatments for inflammatory arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 537-538.	1.4	0
147	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2490.	3.8	566
148	Cardiac Assessment Before Stem Cell Transplantation for Systemic Sclerosisâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1803.	3.8	3
149	Emerging role of epigenetics in systemic sclerosis pathogenesis. <i>Genes and Immunity</i> , 2014, 15, 433-439.	2.2	33
150	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	2.6	182
151	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	2.4	52
152	MiR-29a Reduces TIMP-1 Production by Dermal Fibroblasts via Targeting TGF- β 2 Activated Kinase 1 Binding Protein 1, Implications for Systemic Sclerosis. <i>PLoS ONE</i> , 2014, 9, e115596.	1.1	75
153	Stem cell transplantation in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 719-725.	2.0	25
154	Differentiation Potential of CD14+ Monocytes into Myofibroblasts in Patients with Systemic Sclerosis. <i>PLoS ONE</i> , 2012, 7, e33508.	1.1	41
155	Do high levels of IgA rheumatoid factor indicate a poor response to treatment with TNF inhibitors in patients with RA?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 544-545.	3.2	2
156	Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1402-1403.	0.5	80
157	Scleroderma Lung. <i>Drugs</i> , 2007, 67, 985-996.	4.9	17
158	Antibodies against citrullinated proteins: which test is best?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 652-653.	3.2	0
159	Tweaking Microtubules to Treat Scleroderma. <i>PLoS Medicine</i> , 2005, 2, e415.	3.9	0
160	High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 233-245.	0.7	12
161	Intense Immunosuppression and Stem-Cell Transplantation for Patients with Severe Rheumatic Autoimmune Disease: A Review. <i>Cancer Control</i> , 2003, 10, 57-65.	0.7	38
162	High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety, and efficacy. <i>Arthritis and Rheumatism</i> , 2001, 44, 754-760.	6.7	110

#	ARTICLE	IF	CITATIONS
163	Intensive immunosuppression and autologous stem cell transplantation for patients with severe rheumatoid arthritis: the Leiden experience. <i>Journal of rheumatology Supplement, The</i> , 2001, 64, 25-7.	2.2	8
164	Rheumatoid vasculitis presenting as appendicitis. <i>Clinical and Experimental Rheumatology</i> , 1998, 16, 736-8.	0.4	10
165	Co-Morbidities after Daily Concomitant Treatment with 10 Mg Prednisone or Placebo in the 2 Year Computer-Assisted Management in Early Rheumatoid Arthritis Trial II. <i>Rheumatology</i> , 0, , .	0.9	0
166	Classification of rheumatoid arthritis into active or inactive with a modified Disease Activity score, for future use as a treat-to-target tool, with a HandScan score replacing joint counts. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	0